- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02598856
Bioavailability of Nasal Naloxone and Injected Naloxone Compared (OPI-15-002)
Bioavailability of Nasal Naloxone and Injected Naloxone Compared. A Randomized, Open Label, 4-way Cross-over Study
Opioid overdoses have in the last decade counted for about 230 untimely deaths annually in Norway. The government is currently implementing a strategy for combating this epidemic. Among the actions promoted in this strategy is the distribution of naloxone for intranasal administration. Such administration of naloxone is currently being implemented and tried out around the world, but very little has been done to pharmacologically study this new route of administration of this well known drug, and only 3 open label randomized controlled trials (RCTs) have been conducted. A recent guideline from the WHO on community management of opioid overdoses is a comprehensive review of many of the aspects the investigators cover in our research.
Regarding both dosage, routes of administration of naloxone and care of these patients in the pre hospital setting. The WHO calls for nasal formulations with a higher concentration, as well as focuses on the current wide spread off label use of nasal naloxone as a problem and identifies several research questions of critical importance and very low evidence.The current study, together with our research group's previous and future studies, aims to provide data for the development of a medicinal product with marketing authorisation for use in pre-hospital overdoses. This to contribute to public health measures for opioid users and those around them.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Trondheim, Norway
- Department of Circulation and Medical Imaging
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
In order to participate in this study the subjects must meet all of the following inclusion criteria:
- Provision of a signed written informed consent
- ECG without any pathological abnormalities
- Have a BMI range of 18.5- 26.0 kg/m
- Female subject with child bearing potential must use high efficacy contraception. For the purpose of this study acceptable contraception is defined as sterilization, oral contraceptives, patch, implants, vaginal ring, hormonal IUD or copper IUD through out the study until the last visit.
Laboratory values within reference values for the following haematology and biochemistry tests:
- Haemoglobin
- Creatinine
- ASAT
- ALAT
- Gamma GT
Exclusion Criteria:
In order to participate in the study subjects must not meet any of the following exclusion criteria:
- using medication on a regular basis, including regular use of nasal spray of any form.
- History of prior drug allergy
- local nasal disease or nasal surgery for the last 2 months
- Pregnant or breast feeding women. A serum HCG below 3 U/L must be demonstrated in females of child-bearing potential at Screening Visit.
- Current drug or alcohol abuse, which in the opinion of the Investigator should preclude participation in the study.
- Having received another new medical chemical entity (defined as a compound which has not been approved for marketing) or having participated in any other clinical study that included drug treatment within 3 months of the administration of investigational product in this study.
- Hypersensitivity to naloxone or any of its excipients.
- Investigator considers subject unlikely to comply with study procedures, restrictions and/or other requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intranasal naloxone 1x
Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order.
The four doses will be given at four different visits with a washout period of at least 72 hours between.
One follow-up visit will be conducted within one month after the last exposure.
|
Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from.
IV bolus will be given rapidly (in less than 5 seconds)
Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
|
ACTIVE_COMPARATOR: Intranasal naloxone 2x
Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order.
The four doses will be given at four different visits with a washout period of at least 72 hours between.
One follow-up visit will be conducted within one month after the last exposure.
|
Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from.
IV bolus will be given rapidly (in less than 5 seconds)
Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
|
ACTIVE_COMPARATOR: Intravenous naloxone
Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order.
The four doses will be given at four different visits with a washout period of at least 72 hours between.
One follow-up visit will be conducted within one month after the last exposure.
|
Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from.
IV bolus will be given rapidly (in less than 5 seconds)
Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
|
ACTIVE_COMPARATOR: Intramuscular naloxone
Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order.
The four doses will be given at four different visits with a washout period of at least 72 hours between.
One follow-up visit will be conducted within one month after the last exposure.
|
Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from.
IV bolus will be given rapidly (in less than 5 seconds)
Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in Peak plasma concentration (Cmax)
Time Frame: 4 days
|
Cmax will be compared for single dose IN, IM and IV naloxone
|
4 days
|
Difference in systemic exposure: Area under the plasma concentration versus time curve (AUC-0last)
Time Frame: 4 days
|
AUC 0-last will be compared for single dose IN, IM and IV naloxone
|
4 days
|
Difference in dose adjusted systemic exposure: Area under the plasma concentration versus time curve (AUC-0inf)
Time Frame: 4 days
|
AUC0-inf will be compared for single dose IN, IM and IV naloxone
|
4 days
|
Difference in time at which the Cmax is observed (Tmax)
Time Frame: 4 days
|
Tmax will be compared for single dose IN, IM and IV naloxone
|
4 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose proportionality
Time Frame: 4 days
|
assessed by comparing systemic exposure (AUC0-last) following one and two doses of 1.4 mg of IN naloxone in the same nostril.
|
4 days
|
Absolute bioavailability
Time Frame: 4 days
|
assessed by comparing dose adjusted systemic exposure (AUC0-last) of IN and IV naloxone
|
4 days
|
Relative bioavailability
Time Frame: 4 days
|
assessed by comparing dose adjusted systemic exposure (AUC0-last) of IN and IM naloxone
|
4 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPI 15-002
- 2015-002355-10 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Overdose
-
NHS Greater Glasgow and ClydePublic Health ScotlandRecruitingDrug Effect | Drug Use | Drug Abuse | Drug Toxicity | Illicit Drug Use | Overdose, Drug | Illicit Drug Overdose | Illicit Drug IntoxicationUnited Kingdom
-
Oregon Health and Science UniversityOregon State University; Oregon Department of Corrections; CODA Inc.; Bridgeway... and other collaboratorsCompleted
-
Emergent BioSolutionsCompletedOpioid OverdoseUnited States
-
University Hospital Bispebjerg and FrederiksbergCompletedDrug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
San Francisco Department of Public HealthCompletedOpioid-Related Disorders | Drug OverdoseUnited States
-
San Francisco Department of Public HealthRecruitingStimulant Overdose | Overdose Accidental | Overdose Cocaine | Overdose MethamphetamineUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Substance Abuse | Drug Overdose | Drug Abuse | Drug AddictionUnited States
-
Mikkel Bring ChristensenCompletedBlood Pressure | Drug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
Nationwide Children's HospitalRecruitingHarm Reduction | Opiate Overdose | Fentanyl OverdoseUnited States
-
Nationwide Children's HospitalRecruitingHarm Reduction | Opiate Overdose | Fentanyl OverdoseUnited States
Clinical Trials on Intranasal (IN) naloxone 1x
-
Norwegian University of Science and TechnologyOslo University Hospital; St. Olavs HospitalCompletedOverdose | Drug AbuseNorway
-
Bastyr UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Norwegian University of Science and TechnologySt. Olavs Hospital; University of IcelandCompleted
-
Parc de Salut MarFood and Drug Administration (FDA)Recruiting
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
Leiden University Medical CenterU.S. Food and Drug Administration (FDA)RecruitingChronic Opioid Use | Opioid Induced Respiratory DepressionNetherlands
-
Isfahan University of Medical SciencesCompletedMorphinan Opioid OverdoseIran, Islamic Republic of
-
MD Stem CellsRecruitingStroke | Nervous System Diseases | Diabetic Neuropathies | Neurodegenerative Diseases | Cognitive Impairment | Amyotrophic Lateral Sclerosis | Dementia | Neurological Disorders | Alzheimer Disease | ALS | Traumatic Brain Injury | Cerebral Infarction | Lewy Body Disease | Cerebral Hemorrhage | Frontotemporal Dementia | Progressive... and other conditionsUnited States, United Arab Emirates
-
University of Maryland, BaltimoreRecruitingPain | Virtual Reality | PlaceboUnited States